172 related articles for article (PubMed ID: 38110304)
21. A hybrid design for dose-finding oncology clinical trials.
Liao JJZ; Zhou F; Zhou H; Petruzzelli L; Hou K; Asatiani E
Int J Cancer; 2022 Nov; 151(9):1602-1610. PubMed ID: 35802470
[TBL] [Abstract][Full Text] [Related]
22. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
Ishizuka N; Ohashi Y
Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
[TBL] [Abstract][Full Text] [Related]
23. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
Takeda K; Zhu J; Li R; Yamaguchi Y
Pharm Stat; 2023; 22(6):1104-1115. PubMed ID: 37545018
[TBL] [Abstract][Full Text] [Related]
24. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
Wang S; Tan M
J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
[TBL] [Abstract][Full Text] [Related]
25. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
[TBL] [Abstract][Full Text] [Related]
26. Adaptive design for identifying maximum tolerated dose early to accelerate dose-finding trial.
Kojima M
BMC Med Res Methodol; 2022 Apr; 22(1):97. PubMed ID: 35382745
[TBL] [Abstract][Full Text] [Related]
27. Bayesian hybrid dose-finding design in phase I oncology clinical trials.
Yuan Y; Yin G
Stat Med; 2011 Jul; 30(17):2098-108. PubMed ID: 21365672
[TBL] [Abstract][Full Text] [Related]
28. Comparative review of novel model-assisted designs for phase I clinical trials.
Zhou H; Murray TA; Pan H; Yuan Y
Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
[TBL] [Abstract][Full Text] [Related]
29. Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy.
Liu R; Lin J; Li P
Contemp Clin Trials; 2020 Sep; 96():106083. PubMed ID: 32659438
[TBL] [Abstract][Full Text] [Related]
30. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
31. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
Guo B; Li Y
BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
[TBL] [Abstract][Full Text] [Related]
32. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
Takeda K; Morita S; Taguri M
Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
[TBL] [Abstract][Full Text] [Related]
33. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
Takeda K; Komatsu K; Morita S
Pharm Stat; 2018 Nov; 17(6):725-733. PubMed ID: 30066356
[TBL] [Abstract][Full Text] [Related]
34. Optimal dose escalation methods using deep reinforcement learning in phase I oncology trials.
Matsuura K; Sakamaki K; Honda J; Sozu T
J Biopharm Stat; 2023 Sep; 33(5):639-652. PubMed ID: 36717962
[TBL] [Abstract][Full Text] [Related]
35. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
[TBL] [Abstract][Full Text] [Related]
36. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
James GD; Symeonides SN; Marshall J; Young J; Clack G
BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
[TBL] [Abstract][Full Text] [Related]
37. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
[TBL] [Abstract][Full Text] [Related]
38. Continual reassessment method with regularization in phase I clinical trials.
Li X; Ivanova A; Tian H; Lim P; Liu K
J Biopharm Stat; 2020 Nov; 30(6):964-978. PubMed ID: 32926652
[TBL] [Abstract][Full Text] [Related]
39. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
Takahashi A; Suzuki T
Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
[TBL] [Abstract][Full Text] [Related]
40. Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.
Ursino M; Zohar S; Lentz F; Alberti C; Friede T; Stallard N; Comets E
Biom J; 2017 Jul; 59(4):804-825. PubMed ID: 28321893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
